1-8 of 8
Michelle A. Baron
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Clinical Impact of ITCA 650, a Novel Drug-Device GLP-1 Receptor Agonist, in Uncontrolled Type 2 Diabetes and Very High Baseline HbA1c: The FREEDOM-1 HBL (High Baseline) Study

Robert R. Henry, Julio Rosenstock, Douglas S. Denham, Prakash Prabhakar, Lise Kjems, Michelle A. Baron
Journal: Diabetes Care
Diabetes Care 2018;41(3):613–619
https://doi.org/10.2337/dc17-1519
Published: 04 January 2018
View article titled, Clinical Impact of ITCA 650, a Novel Drug-Device GLP-1 Receptor Agonist, in Uncontrolled Type 2 Diabetes and Very High Baseline HbA<sub>1c</sub>: The FREEDOM-1 HBL (High Baseline) Study
Open the PDF for Clinical Impact of ITCA 650, a Novel Drug-Device GLP-1 Receptor Agonist, in Uncontrolled Type 2 Diabetes and Very High Baseline HbA<sub>1c</sub>: The FREEDOM-1 HBL (High Baseline) Study in another window
Includes: Supplementary data
Journal Articles

Efficacy and Safety of ITCA 650, a Novel Drug-Device GLP-1 Receptor Agonist, in Type 2 Diabetes Uncontrolled With Oral Antidiabetes Drugs: The FREEDOM-1 Trial

Julio Rosenstock, John B. Buse, Rehan Azeem, Prakash Prabhakar, Lise Kjems, Holly Huang, Michelle A. Baron
Journal: Diabetes Care
Diabetes Care 2018;41(2):333–340
https://doi.org/10.2337/dc17-1306
Published: 14 December 2017
View article titled, Efficacy and Safety of ITCA 650, a Novel Drug-Device GLP-1 Receptor Agonist, in Type 2 Diabetes Uncontrolled With Oral Antidiabetes Drugs: The FREEDOM-1 Trial
Open the PDF for Efficacy and Safety of ITCA 650, a Novel Drug-Device GLP-1 Receptor Agonist, in Type 2 Diabetes Uncontrolled With Oral Antidiabetes Drugs: The FREEDOM-1 Trial in another window
Includes: Supplementary data
Journal Articles

Randomized Trial of Continuous Subcutaneous Delivery of Exenatide by ITCA 650 Versus Twice-Daily Exenatide Injections in Metformin-Treated Type 2 Diabetes. Diabetes Care 2013;36: 2559–2565

Robert R. Henry, Julio Rosenstock, Douglas K. Logan, Thomas R. Alessi, Kenneth Luskey, Michelle A. Baron
Journal: Diabetes Care
Diabetes Care 2014;37(1):312
https://doi.org/10.2337/dc14-er01b
Published: 11 December 2013
View article titled, Randomized Trial of Continuous Subcutaneous Delivery of Exenatide by ITCA 650 Versus Twice-Daily Exenatide Injections in Metformin-Treated Type 2 Diabetes. Diabetes Care 2013;36: 2559–2565
Open the PDF for Randomized Trial of Continuous Subcutaneous Delivery of Exenatide by ITCA 650 Versus Twice-Daily Exenatide Injections in Metformin-Treated Type 2 Diabetes. Diabetes Care 2013;36: 2559–2565 in another window
Journal Articles

Randomized Trial of Continuous Subcutaneous Delivery of Exenatide by ITCA 650 Versus Twice-Daily Exenatide Injections in Metformin-Treated Type 2 Diabetes

Robert R. Henry, MD, Julio Rosenstock, MD, Douglas K. Logan, MD, Thomas R. Alessi, PHD, Kenneth Luskey, MD, Michelle A. Baron, MD
Journal: Diabetes Care
Diabetes Care 2013;36(9):2559–2565
https://doi.org/10.2337/dc12-2410
Published: 13 August 2013
View article titled, Randomized Trial of Continuous Subcutaneous Delivery of Exenatide by ITCA 650 Versus Twice-Daily Exenatide Injections in Metformin-Treated Type 2 Diabetes
Open the PDF for Randomized Trial of Continuous Subcutaneous Delivery of Exenatide by ITCA 650 Versus Twice-Daily Exenatide Injections in Metformin-Treated Type 2 Diabetes in another window
Includes: Supplementary data
Journal Articles

Effects of the Dipeptidyl Peptidase-IV Inhibitor Vildagliptin on Incretin Hormones, Islet Function, and Postprandial Glycemia in Subjects With Impaired Glucose Tolerance

Julio Rosenstock, MD, James E. Foley, PHD, Marc Rendell, MD, Mona Landin-Olsson, MD, PHD, Jens J. Holst, MD, Carolyn F. Deacon, PHD, Erika Rochotte, MSC, Michelle A. Baron, MD
Journal: Diabetes Care
Diabetes Care 2008;31(1):30–35
https://doi.org/10.2337/dc07-1616
Published: 01 January 2008
View article titled, Effects of the Dipeptidyl Peptidase-IV Inhibitor Vildagliptin on Incretin Hormones, Islet Function, and Postprandial Glycemia in Subjects With Impaired Glucose Tolerance
Open the PDF for Effects of the Dipeptidyl Peptidase-IV Inhibitor Vildagliptin on Incretin Hormones, Islet Function, and Postprandial Glycemia in Subjects With Impaired Glucose Tolerance in another window
Includes: Supplementary data
Journal Articles

Comparison of Vildagliptin and Rosiglitazone Monotherapy in Patients With Type 2 Diabetes: A 24-week, double-blind, randomized trial

Julio Rosenstock, MD, Michelle A. Baron, MD, Sylvie Dejager, MD, PHD, David Mills, MSC, Anja Schweizer, PHD
Journal: Diabetes Care
Diabetes Care 2007;30(2):217–223
https://doi.org/10.2337/dc06-1815
Published: 01 February 2007
View article titled, Comparison of Vildagliptin and Rosiglitazone Monotherapy in Patients With Type 2 Diabetes: <subtitle>A 24-week, double-blind, randomized trial</subtitle>
Open the PDF for Comparison of Vildagliptin and Rosiglitazone Monotherapy in Patients With Type 2 Diabetes: <subtitle>A 24-week, double-blind, randomized trial</subtitle> in another window
Journal Articles

PRESERVE-β: Two-year efficacy and safety of initial combination therapy with nateglinide or glyburide plus metformin

John Gerich, MD, Philip Raskin, MD, Lisa Jean-Louis, Das Purkayastha, PHD, Michelle A. Baron, MD
Journal: Diabetes Care
Diabetes Care 2005;28(9):2093–2099
https://doi.org/10.2337/diacare.28.9.2093
Published: 01 September 2005
View article titled, PRESERVE-β: <subtitle>Two-year efficacy and safety of initial combination therapy with nateglinide or glyburide plus metformin</subtitle>
Open the PDF for PRESERVE-β: <subtitle>Two-year efficacy and safety of initial combination therapy with nateglinide or glyburide plus metformin</subtitle> in another window
Journal Articles

Comparison of Repaglinide and Nateglinide in Combination With Metformin: Response to Raskin et al.

Michelle A. Baron, MD
Journal: Diabetes Care
Diabetes Care 2003;26(12):3361–3362
https://doi.org/10.2337/diacare.26.12.3361-a
Published: 01 December 2003
View article titled, Comparison of Repaglinide and Nateglinide in Combination With Metformin: <subtitle>Response to Raskin et al. </subtitle>
Open the PDF for Comparison of Repaglinide and Nateglinide in Combination With Metformin: <subtitle>Response to Raskin et al. </subtitle> in another window